linjc16/ctgov huggingface dataset:
COVID-19 Immunity and Changes Over Time

Study Overview
=================
Brief Summary
-----------------
The risk of household spread of SARS-CoV-2 hinges on both the transmission dynamics of the virus circulating in the community as well as the seroprotection pattern of constituent members, which can be attributed to vaccination and previous infections. This study is conceptualised to assess the dynamicity of SARS-CoV-2 risk at the household level, through monitoring the pattern of seroprotection, in conjunction with the vaccination coverage, history of infection and exposure risk in the setting of Hong Kong.

Detailed Description
-----------------
The aim of this study is to assess the SARS-CoV-2 risk at the household level, with the objectives of (a) determining the coverage of vaccination and its changes over time; (b) monitoring pattern of exposure and history of infection; and (c) evaluating the level of seroprotection and its longitudinal trend. A cohort of households comprising 900 persons would be recruited. Invited participants would be attend the Research Centre for blood sampling and the completion of a simple questionnaire at 3 different timepoints at 12-18 months apart. A questionnaire would be administered to capture the following characteristics: (a) Socio-demographics; (b) History of SARS-CoV-2 infection; (c) adoption of precautionary measures; (d) SARS-CoV-2 testing history and (e) SARS-CoV-2 vaccination uptake. Participants would be tested for SARS-CoV-2 serology. The main markers for measurement are nucleocapsid antibody for inferring past infection, spike antibody for the immunological responses, and seroprotection by SARS-CoV-2 surrogate virus neutralisation test.

Official Title
-----------------
Patterns of SARS-CoV-2 Immunity at Household Level and Their Changes Over Time

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults of age 18 or above, or children under the age of 18 with informed consent of the legal guardian normally residing in Hong Kong could communicate in spoken and written Chinese and/or English Exclusion Criteria: individuals with mental illness prisoners
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of participants with COVID-19 protective immunity | Prevalence of SARS-CoV-2 spike antibody | 1 year | 
| Proportion of participants with marker of past COVID-19 infection | Prevalence of SARS-CoV-2 nucleocapsid antibody | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
serology, cohort study, SARS-CoV-2 antibody
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Study Overview
=================
Brief Summary
-----------------
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.

Official Title
-----------------
Long-Term Follow-up Protocol for Subjects Treated With a CAR T-Cell Product on a Juno-Sponsored Clinical Trial

Conditions
-----------------
Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

Intervention / Treatment
-----------------
* Genetic: JCAR017
* Genetic: JCARH125


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have received at least one dose of a Juno CAR T-cell product (listed above) in a Juno-sponsored clinical trial Patients who have provided informed consent for the long-term follow-up study Exclusion Criteria: None. All patients who have previously received treatment with a Juno CAR T-cell product are eligible for this long-term follow-up study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| JCAR017-treated<br>Patients who received previous treatment with JCAR017 | Genetic: JCAR017<br>* No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.<br>|
| JCARH125-treated<br>Patients who received previous treatment with JCARH125 | Genetic: JCARH125<br>* No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with adverse events |  | 15 years from last treatment | 
| Proportion of patients with detectable viral vector sequences |  | 15 years from last treatment | 
| Proportion of patients with detectable RCR or RCL |  | 15 years from last treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 15 years from last treatment | 
| Progression-free survival |  | 15 years from last treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
long-term follow-up, chimeric antigen receptor (CAR) T cells, JCAR017, JCARH125
Comparison of ARDS COVID-19 (WHO) vs ARDS Influenza in the ICU

Study Overview
=================
Brief Summary
-----------------
Since the beginning of the SARS CoV 2 pandemia, the SARS CoV 2 was frequently compared with the seasonal influenza virus. However, few studies compared patients presenting acute respiratory distress syndrome (ARDS) induced by these viruses, with results being discordant. Our study means to compare mortality and morbidity of patients hospitalized in an intensive care unit (ICU) with ARDS induced by SARS CoV-2 and seasonal influenza.

Official Title
-----------------
Clinical Outcomes and Characteristics of Critically Ill Patients With Influenza and COVID-19 Induced ARDS: a Retrospective, Matched Cohort Study

Conditions
-----------------
ARDS, COVID-19 Acute Respiratory Distress Syndrome, Influenza

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients hospitalized in ICU under mechanical ventilation presenting an ARDS according to the Berlin definition induced by either influenza or SARS CoV 2 Exclusion Criteria: pregnant women mechanical ventilation>48 hours before admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with ARDS induced by SARS CoV 2<br> | Other: no intervention<br>* no intervention, retrospective comparison<br>|
| patients with ARDS induced by influenza<br> | Other: no intervention<br>* no intervention, retrospective comparison<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | at 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of stay in ICU |  | at 28 days | 
| length of mechanical ventilation |  | at 28 days | 
| length of vasopressors |  | at 28 days | 
| length of extrarenal epuration |  | at 28 days | 
| amount of drugs for sedation |  | at 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ards
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment

Study Overview
=================
Brief Summary
-----------------
This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.

Official Title
-----------------
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment

Conditions
-----------------
Muscle Spasticity

Intervention / Treatment
-----------------
* Drug: onabotulinumtoxinA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treatment with onabotulinumtoxinA according to the decision of the physician for spasticity Willingness to complete study questionnaires and answer study questions by phone or internet Exclusion Criteria: Concurrent participation in a clinical trial for spasticity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| onabotulinumtoxinA<br>onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician. | Drug: onabotulinumtoxinA<br>* onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.<br>* Other names: botulinum toxin Type A;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Patients Reporting Satisfaction with Treatment |  | 5 Weeks | 
| Percentage of Health Care Providers Reporting Satisfaction with Treatment |  | 12 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physical Functioning on a 5-Point Scale |  | 5 Weeks | 
| Severity of Pain on an 11-Point Scale |  | 5 Weeks | 
| Disability Assessment on a 4-Point Scale |  | 12 Weeks |
Observational Study of Keloids Scars Treated by Shaving and Cryosurgery

Study Overview
=================
Brief Summary
-----------------
Treatment of keloids scars is difficult and controversial. These keloids have a functional and aesthetic impact. A lot of treatment are described with a lot of relapses and aggravation. Authors report outcomes of the treatment with shaving and cryosurgery

Conditions
-----------------
Keloids Scars

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: keloids scars treatment of shaving and cryosurgery Exclusion Criteria: immunosuppressive therapy chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| size scar | reduction size scar | Inclusion and one years after | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Keloids, Shaving, Ears, Cryosurgery, Hypertrophic scars
Life Quality Determinant Assessment of Fibromyalgia Patients

Study Overview
=================
Brief Summary
-----------------
The primary purpose is the evaluation of life quality of Fibromyalgia patients. The investigators' main hypothesis includes the role of geographical, sociological, psychological and physical activity on life quality.

Official Title
-----------------
Life Quality Determinant Assessment of Fibromyalgia Patients Related to Health Devices

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Behavioral: Physical activity.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Age group : 20 to 60 Male or female American College of Rheumatology criteria Social Security beneficiary Informed consent of the patient Patient informed of the medical examination prior to inclusion Patient residing in the Bas-Rhin area Exclusion Criteria: No medical objections to performing a stress test Any cardio-respiratory and musculoskeletal affection preventing physical activity Any particular clinical form disease Patient in situation of exclusion Subject incapacity to understand informed consent Patient deprived of freedom or under the protection of a conservator Pregnancy or breast-feeding

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rehab Institute<br>This group will do some physical activity in a specialized institute | Behavioral: Physical activity.<br>* Have subject do moderate physical activity.<br>|
| Active Comparator: Club structure<br>This group will do some physical activity in a club. | Behavioral: Physical activity.<br>* Have subject do moderate physical activity.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Life with Fibromyalgia score on questionnary QIF (Quality of Life with Fibromyalgia) |  | 6th month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score on questionnary Short Form (36) SF36 |  | 6th month | 
| Measurement of displacement with Global Positioning System GPS |  | 6th month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality of Life, Physical Activity
Aripiprazole Treatment of Prodromal Patients

Study Overview
=================
Brief Summary
-----------------
We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.

Detailed Description
-----------------
This is an 8 week trial with extension for responders out to one year. All patients receive active medication; there is no placebo. Patients must meet criteria for the schizophrenia prodrome according to the Structured Interview for Prodromal Syndromes. Patients receive counseling as well. All counseling and medication are free of charge.

Official Title
-----------------
Aripiprazole Treatment of Prodromal Patients

Conditions
-----------------
Schizophrenia, Psychosis

Intervention / Treatment
-----------------
* Drug: Aripiprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 13 to 40 meet criteria for the prodrome for schizophrenia Exclusion Criteria: history of psychosis

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Aripiprazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Score of the Scale Of Prodromal Symptoms | This is a 19-item scale with items scores 0-6. Treatment response is defined as all 5 Scale of Prodromal Syndromes positive symtpom items being rate below the prodromal range (< or equal to 2). | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prodrome, ultra high risk, aripiprazole
Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

Study Overview
=================
Brief Summary
-----------------
Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with ulcerative colitis (UC) and Crohn's disease (CD), experience clinical, biochemical and genetical improvement in their disease. A prospective randomised study comparing the mushroom extract with placebo.

Official Title
-----------------
Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study

Conditions
-----------------
Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease

Intervention / Treatment
-----------------
* Dietary Supplement: AndoSan
* Dietary Supplement: Sugar Extract


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: moderate disease Exclusion Criteria: serious disease, biological treatment, pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: AndoSan<br>AndoSan given to IBD patients | Dietary Supplement: AndoSan<br>* AndoSan 30 ml x 2 for 21 days<br>|
| Sham Comparator: Sugar extract<br>Sugar extract to IBD patients | Dietary Supplement: Sugar Extract<br>* Sham comparator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in biochemical blood parameters (pro-inflammatory cytokines) |  | 21 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of calprotectin in feces. |  | 21 days | 
| Clinical symptom score. |  | 21 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cytokine levels in blood, Calprotectin in feces, Clinical symptom score.
Plant Stanol Ester Beverage and Ileostoma Patients

Study Overview
=================
Brief Summary
-----------------
We aim to examine efficacy of a plant stanolester beverage to lower serum cholesterol and LDL-cholesterol levels, when given with or without a fatty acid preparation. Study subjects are otherwise healthy proctocolectomized ileostoma patients (n=10), who consume stanolester beverage with or without a fatty acid preparation in a random order for one week period after a standardized low-fat meal. Washout period is 4 weeks. Serum lipids, lipoprotein lipids, sterols and fecal sterols and variables of cholesterol metabolism will be examined accordingly.

Official Title
-----------------
Effects of a Plant Stanolester Beverage on Cholesterol Metabolism Among Human Subjects With Ileostoma

Conditions
-----------------
Ileostoma

Intervention / Treatment
-----------------
* Dietary Supplement: Plant stanolester and fatty acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy proctocolectomized subjects with an ileostoma Exclusion Criteria: Chronic illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum cholesterol level |  | After treatment perdiods | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cholesterol, Plant stanolester, Beverage, Ileostoma, Serum cholesterol level, serum LDL-cholesterol level, Intestinal cholesterol absorption efficiency
Simvatstatin Used to Treat Pulmonary Hypertension

Study Overview
=================
Brief Summary
-----------------
we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.

Detailed Description
-----------------
advanced pulmonary hypertension is refractory to the medication in use nowaday, especially pulmonary hypertension secondary to congenital heart disease or chronic pulmonary embolism.It is revealed that statins may intefere the pathogenisis of the pulmonary hypertension in many key poing, such as improving apotosis or inhiting the proliferation of pulmonary vascular smooth muscle cell. so we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.

Official Title
-----------------
the Clinical Research Using Simvastatin as a Medication to Treat Advanced Secondary Pulmonary Hypertension

Conditions
-----------------
Hypertension, Pulmonary

Intervention / Treatment
-----------------
* Drug: simvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pasp>50mmHg Exclusion Criteria: pasp<50mmhg

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1simvastatin group<br>before the operation, the patient start the simvastatin medication on the dosage of 40mg per day | Drug: simvastatin<br>* medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation<br>|
| No Intervention: 2contral group<br>just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the simvastatin can alleviate pulmonary hypertension |  |  | 
| pulmonary pressure |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| simvastatin can highten the perioperative and long term survaval rate and the living quality |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pulmonary hypertension, simvastatin, advanced pulmonary hypertension secondary to congenital heart disease, advanced pulmonary hypertension secondary to chronic pulmonary embolism